EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features

American Journal of Transplantation

Volumn 16, Issue 2, 2016, Pages 414-425

  Finalet Ferreiro, J ^a   Morscio, J ^b   Dierickx, D ^b   Vandenberghe, P ^a   Gheysens, O ^b   Verhoef, G ^b   Zamani, M ^a   Tousseyn, T ^b   Wlodarska, Iwona ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROGRAMMED DEATH 1 LIGAND 2; MESSENGER RNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CDKNA2 GENE; CHILD; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOXP1 GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; ONCOGENE; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TNFAIP3 GENE; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; YOUNG ADULT; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; ENZYME IMMUNOASSAY; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSTOPERATIVE COMPLICATION; PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; GRAFT REJECTION; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84957990039     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13558     Document Type: Article

References (38)

1. Swerdlow SH, Campo E, Harris NL, et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
2. Poirel HA, Bernheim A, Schneider A, et al., Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: Correlation with histopathological subcategories and EBV status. Transplantation 2005; 80: 176-184.
3. Rinaldi A, Kwee I, Poretti G, et al., Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol 2006; 134: 27-36.
4. Rinaldi A, Capello D, Scandurra M, et al., Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol 2010; 149: 569-577.
5. Morscio J, Dierickx D, Ferreiro JF, et al., Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 2013; 13: 1305-1316.
6. Craig FE, Johnson LR, Harvey SA, et al., Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol 2007; 16: 158-168.
7. Hans CP, Weisenburger DD, Greiner TC, et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
8. Hamilton-Dutoit SJ, Rea D, Raphael M, et al., Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993; 143: 1072-1085.
9. Bea S, Zettl A, Wright G, et al., Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183-3190.
10. Lenz G, Wright GW, Emre NC, et al., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105: 13520-13525.
11. Delecluse HJ, Rouault JP, Jeammot B, Kremmer E, Bastard C, Berger F., Bcl6/Laz3 rearrangements in post-transplant lymphoproliferative disorders. Br J Haematol 1995; 91: 101-103.
12. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-245.
13. Djokic M, Le Beau MM, Swinnen LJ, et al., Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 2006; 45: 313-318.
14. Green MR, Monti S, Rodig SJ, et al., Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-3277.
15. Steidl C, Telenius A, Shah SP, et al., Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010; 116: 418-427.
16. Van Roosbroeck K, Cox L, Tousseyn T, et al., JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011; 117: 4056-4064.
17. Vandenberghe P, Wlodarska I, Tousseyn T, et al., Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study. Lancet Haematol 2015; 2: e55-e65.
18. Keir ME, Butte MJ, Freeman GJ, Sharpe AH., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
19. Green MR, Rodig S, Juszczynski P, et al., Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 2012; 18: 1611-1618.
20. Chen BJ, Chapuy B, Ouyang J, et al., PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462-3473.
21. Ansell SM, Lesokhin AM, Borrello I, et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319.
22. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA., Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
23. LaPak KM, Burd CE., The molecular balancing act of p16(INK4a) in cancer and aging. Mol Cancer Res 2014; 12 (2): 167-183.
24. Romagosa C, Simonetti S, Lopez-Vicente L, et al., p16(Ink4a) overexpression in cancer: A tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30: 2087-2097.
25. Koon HB, Ippolito GC, Banham AH, Tucker PW., FOXP1: A potential therapeutic target in cancer. Expert Opin Ther Targets 2007; 11: 955-965.
26. Wlodarska I, Veyt E, De Paepe P, et al., FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299-1305.
27. Rouhigharabaei L, Finalet FJ, Tousseyn T, et al., Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1. PLoS One 2014; 9: e85851.
28. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS., Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-2935.
29. Price AM, Tourigny JP, Forte E, Salinas RE, Dave SS, Luftig MA., Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. J Virol 2012; 86: 11096-11106.
30. Leroy K, Haioun C, Lepage E, et al., p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002; 13: 1108-1115.
31. Morscio J, Dierickx D, Nijs J, et al., Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38: 875-886.
32. Yoon H, Park S, Ju H, et al., Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2015; 54: 383-396.
33. Nakamura S, Stein H, Harris NL, Campo E,. EBV positive DLBCL of the elderly. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC, 2015; p. 243-244.
34. Finalet FJ, Morscio J, Dierickx D, et al., Posttransplant molecular Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern 1. Haematologica 2015; 100: e275-e279.
35. Leblond V, Davi F, Charlotte F, et al., Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity ? J Clin Oncol 1998; 16: 2052-2059.
36. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH., Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity ? Am J Surg Pathol 2000; 24: 375-385.
37. Capello D, Rossi D, Gaidano G., Post-transplant lymphoproliferative disorders: Molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005; 23: 61-67.
38. Luskin MR, Heil DS, Tan KS, et al., The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant 2015; 15: 2665-2673.